Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorvotuzumab mertansine
- Development stage
- Phase 2
- Lead developer
- ImmunoGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lorvotuzumab mertansine is an investigational antibody-drug conjugate (ADC) designed for the treatment of CD56-positive cancers, such as small-cell lung cancer, ovarian cancer, multiple myeloma, leukemia, and Merkel cell carcinoma. The drug consists of a humanized monoclonal antibody (lorvotuzumab or huN901) that specifically targets Neural cell adhesion molecule 1 (NCAM1/CD56), conjugated via a cleavable disulfide linker to DM1 (mertansine), a potent microtubule-disrupting cytotoxic agent derived from maytansine. Upon binding to CD56-expressing tumor cells, the ADC is internalized and releases DM1 inside the cell, leading to disruption of microtubules and induction of apoptosis. Lorvotuzumab mertansine has shown promising results in early-phase clinical trials for several malignancies with high CD56 expression and has been granted orphan drug status for Merkel cell carcinoma[1][2][3][4][5][6][8].
- Other names
- lorvotuzumab mertansine
02
Targets
NCAM1 (Neural cell adhesion molecule 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on lorvotuzumab mertansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorvotuzumab mertansine.